- Home
- TPST vs ZYXI Comparison
TPST vs ZYXI Comparison
Compare TPST & ZYXI Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- TPST
- ZYXI
- Stock Information
- Founded
- TPST 2011
- ZYXI 1996
- Country
- TPST United States
- ZYXI United States
- Employees
- TPST N/A
- ZYXI N/A
- Industry
- TPST Biotechnology: Pharmaceutical Preparations
- ZYXI Biotechnology: Electromedical & Electrotherapeutic Apparatus
- Sector
- TPST Health Care
- ZYXI Health Care
- Exchange
- TPST Nasdaq
- ZYXI Nasdaq
- Market Cap
- TPST 45.5M
- ZYXI 44.8M
- IPO Year
- TPST N/A
- ZYXI N/A
- Fundamental
- Price
- TPST $10.45
- ZYXI $1.42
- Analyst Decision
- TPST Hold
- ZYXI Hold
- Analyst Count
- TPST 3
- ZYXI 3
- Target Price
- TPST $30.00
- ZYXI $3.00
- AVG Volume (30 Days)
- TPST 47.7K
- ZYXI 76.0K
- Earning Date
- TPST 11-11-2025
- ZYXI 10-30-2025
- Dividend Yield
- TPST N/A
- ZYXI N/A
- EPS Growth
- TPST N/A
- ZYXI N/A
- EPS
- TPST N/A
- ZYXI N/A
- Revenue
- TPST N/A
- ZYXI $144,808,000.00
- Revenue This Year
- TPST N/A
- ZYXI N/A
- Revenue Next Year
- TPST N/A
- ZYXI $7.07
- P/E Ratio
- TPST N/A
- ZYXI N/A
- Revenue Growth
- TPST N/A
- ZYXI N/A
- 52 Week Low
- TPST $5.35
- ZYXI $1.23
- 52 Week High
- TPST $15.73
- ZYXI $9.42
- Technical
- Relative Strength Index (RSI)
- TPST 49.98
- ZYXI 47.97
- Support Level
- TPST $10.09
- ZYXI $1.33
- Resistance Level
- TPST $10.79
- ZYXI $1.47
- Average True Range (ATR)
- TPST 0.68
- ZYXI 0.08
- MACD
- TPST -0.11
- ZYXI 0.01
- Stochastic Oscillator
- TPST 16.93
- ZYXI 56.07
About TPST Tempest Therapeutics Inc.
Tempest Therapeutics Inc is a late-stage develpment biotechnology company developing small molecule therapeutics to treat cancer through mechanisms that directly kill tumor cells and activate tumor-specific immunity. Its clinical-stage therapeutic product candidates are TPST-1120 and TPST-1495 which are clinical-stage molecules designed to inhibit their respective targets.
About ZYXI Zynex Inc.
Zynex Inc is engaged in the manufacturing and marketing of medical devices. It operates through one primary business segment, Electrotherapy and Pain Management Products. The business activities of the company are carried out through its subsidiaries. The company designs, manufactures, and markets medical devices that treat chronic and acute pain, as well as activate and exercise muscles for rehabilitative purposes with electrical stimulation. The company operates business as one operating segment which includes two revenue types: Devices and Supplies. Its markets Zynex-manufactured products which include NexWave, NeuroMove, InWave E-Wave, and others.